ANITA SABICHI to Humans
This is a "connection" page, showing publications ANITA SABICHI has written about Humans.
Connection Strength
0.219
-
Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder. J Immunother. 2017 04; 40(3):114-116.
Score: 0.015
-
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila). 2011 Oct; 4(10):1580-9.
Score: 0.010
-
Forced COX-2 expression induces PGE(2) and invasion in immortalized urothelial cells. Urol Oncol. 2008 Nov-Dec; 26(6):641-5.
Score: 0.008
-
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
Score: 0.008
-
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):2178-84.
Score: 0.007
-
Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol. 2006 Mar; 175(3 Pt 1):1133-7.
Score: 0.007
-
Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep. 2006 Feb; 15(2):471-7.
Score: 0.007
-
RARbeta1': primed to fight retinoid resistance in lung carcinogenesis. J Natl Cancer Inst. 2005 Nov 16; 97(22):1632-3.
Score: 0.007
-
Peroxisome proliferator-activated receptor-gamma suppresses cyclooxygenase-2 expression in human prostate cells. Cancer Epidemiol Biomarkers Prev. 2004 Nov; 13(11 Pt 1):1704-9.
Score: 0.006
-
COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin Oncol. 2004 Apr; 31(2 Suppl 7):36-44.
Score: 0.006
-
Frontiers in cancer prevention research. Cancer Res. 2003 Sep 15; 63(18):5649-55.
Score: 0.006
-
Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population. Oral Oncol. 2023 10; 145:106536.
Score: 0.006
-
Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clin Cancer Res. 2003 Jul; 9(7):2400-5.
Score: 0.006
-
COX-2 inhibitors and other NSAIDs in bladder and prostate cancer. Prog Exp Tumor Res. 2003; 37:163-78.
Score: 0.006
-
Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access. Cancer Res Commun. 2022 07 26; 2022.
Score: 0.005
-
Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol. 2020 11 01; 38(31):3698-3715.
Score: 0.005
-
Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting. Oral Oncol. 2020 03; 102:104440.
Score: 0.004
-
Primary Spinal Cord Melanoma - An Uncommon Entity. Can J Neurol Sci. 2019 05; 46(3):348-350.
Score: 0.004
-
Cancer chemoprevention: progress and promise. J Natl Cancer Inst. 1998 Oct 21; 90(20):1514-28.
Score: 0.004
-
Nivolumab Treatment for Cancers in the HIV-infected Population. J Immunother. 2018 Oct; 41(8):379-383.
Score: 0.004
-
Retinoids in the chemoprevention of bladder cancer. Curr Opin Oncol. 1998 Sep; 10(5):479-84.
Score: 0.004
-
Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst. 1998 Apr 15; 90(8):597-605.
Score: 0.004
-
Regulation of nuclear oncogenes expressed in lung cancer cell lines. J Cell Biochem Suppl. 1996; 24:218-27.
Score: 0.003
-
Reply to J. Cabezas et al. J Clin Oncol. 2016 Jan 20; 34(3):290-1.
Score: 0.003
-
Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol. 2015 Jul 01; 33(19):2212-20.
Score: 0.003
-
HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer. Mol Cancer Res. 2015 May; 13(5):809-18.
Score: 0.003
-
The molecular biology of lung cancer: application to early detection and prevention. Oncology (Williston Park). 1993 Jun; 7(6):19-26; discussion 31-2, 37.
Score: 0.003
-
Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood. 2013 Jun 06; 121(23):4729-39.
Score: 0.003
-
Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012 Dec; 130(12):1608-11.
Score: 0.003
-
Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012 Jun 13; 307(22):2418-29.
Score: 0.003
-
Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res. 2011 May 01; 17(9):2863-73.
Score: 0.002
-
Three synchronous HPV-associated squamous cell carcinomas of Waldeyer's ring: case report and comparison with Slaughter's model of field cancerization. Head Neck. 2010 Aug; 32(8):1118-24.
Score: 0.002
-
American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol. 2010 Jul 01; 28(19):3199-202.
Score: 0.002
-
Mortality in the randomized, controlled lung intergroup trial of isotretinoin. Cancer Prev Res (Phila). 2010 Jun; 3(6):738-44.
Score: 0.002
-
Identification of genes correlated with early-stage bladder cancer progression. Cancer Prev Res (Phila). 2010 Jun; 3(6):776-86.
Score: 0.002
-
The use of short tandem repeat profiling to characterize human bladder cancer cell lines. J Urol. 2009 Jun; 181(6):2737-48.
Score: 0.002
-
High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009 Jan; 2(1):22-6.
Score: 0.002
-
Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. Mol Carcinog. 2008 Sep; 47(9):678-85.
Score: 0.002
-
Clinical model of cost of bladder cancer in the elderly. Urology. 2008 Mar; 71(3):519-25.
Score: 0.002
-
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007 May 20; 25(15):1974-8.
Score: 0.002
-
Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006 Sep; 68(3):549-53.
Score: 0.002
-
Comparative outcomes of bladder cancer. Obstet Gynecol. 2006 Jul; 108(1):169-75.
Score: 0.002
-
15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene. 2006 Sep 28; 25(44):6015-25.
Score: 0.002
-
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res. 2005 Jul 15; 65(14):6189-98.
Score: 0.002
-
Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1697-702.
Score: 0.002
-
Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res. 2005 Mar 01; 65(5):1808-13.
Score: 0.002
-
Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia. 2005 Mar; 7(3):280-93.
Score: 0.002
-
Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev. 2004 Nov; 13(11 Pt 1):1710-6.
Score: 0.002
-
Focus on bladder cancer. Cancer Cell. 2004 Aug; 6(2):111-6.
Score: 0.002
-
Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem. 2004 Apr 30; 279(18):19191-200.
Score: 0.002
-
The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Ann Thorac Surg. 2003 Oct; 76(4):1001-7; discussion 1007-8.
Score: 0.001
-
Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer. 2003 Sep 20; 106(5):661-5.
Score: 0.001
-
Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol. 2003 Jul-Aug; 21(4):266-70.
Score: 0.001
-
Chemoprevention of superficial bladder cancer. Crit Rev Oncol Hematol. 2002 Sep; 43(3):277-86.
Score: 0.001
-
Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol Biomarkers Prev. 2001 Apr; 10(4):391-5.
Score: 0.001
-
Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res. 2001 Mar 15; 61(6):2720-6.
Score: 0.001
-
Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev. 2000 Nov; 9(11):1171-82.
Score: 0.001
-
cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999 Oct 28; 18(44):6063-70.
Score: 0.001
-
Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. Hum Pathol. 1999 Mar; 30(3):257-62.
Score: 0.001
-
Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin. J Natl Cancer Inst. 1999 Jan 20; 91(2):135-43.
Score: 0.001
-
Molecular characterization of adenocarcinoma of the cervix. Gynecol Oncol. 1997 Feb; 64(2):242-51.
Score: 0.001
-
Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene. 1995 Dec 21; 11(12):2639-48.
Score: 0.001
-
Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression. Blood. 1991 Sep 15; 78(6):1503-15.
Score: 0.001